Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results
|
|
- Brett Harris
- 5 years ago
- Views:
Transcription
1 Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results Pennan Barry, MD, MPH Grace Lin, MS September 6, 08 Curry International Tuberculosis Center Learning Objectives By the end of the training, participants will be able to: describe the principles behind the Xpert MTB/RIF test identify circumstances that should trigger additional testing or where false identification of MTB/RIF resistance should be suspected identify probes that most frequently detect mutations conferring RIF resistance and silent mutations not conferring RIF resistance identify situations where additional Xpert testing is not indicated Xpert interpretatiom-curry Center-9/6/8 September 6, 08
2 None Disclosures Xpert interpretatiom-curry Center-9/6/8 3 Agenda Intro: Not an introduction to Xpert use Not about release from respiratory isolation What is Xpert and how does it work? Case discussions: Illustrate nuances of Xpert interpretation (focus on RIF resistance result) When to ask for more info or more testing When not to test more Xpert interpretatiom-curry Center-9/6/8 4 September 6, 08
3 Xpert MTB/RIF assay Great tool for TB detection FDA Approved Shortens time significantly Testing time. hr; Easy to perform Real-Time PCR molecular beacon probes rpob gene (core region, codons 07-33) Xpert Clinical Report Xpert interpretatiom-curry Center-9/6/8 6 September 6, 08 3
4 Hidden Info: Report on Xpert computer Xpert interpretatiom-curry Center-9/6/8 7 Methodology: Realtime PCR Realtime PCR = PCR + probes PCR = Polymerase Chain Reaction Generates copies of specific segments of DNA DNA copies double with each PCR cycle Probes report whether specific sequence is present Probes bind to amplicons; generate signals with each PCR cycle PCR cycles Xpert interpretatiom-curry Center-9/6/8 8 September 6, 08 4
5 PCR Cycles 9 Molecular Beacon probe (Hairpin structure head & two arms) Head (functional part, MTBC sequence, ~0 nt) Two arms (-7 nt) Fluorophore Quencher At rest stage, two arms bind together forming a stem. Fluorophore is quenched. No signals are produced. 0 September 6, 08
6 Fluorescence produced by probe binding Experts on Xpert: A Laboratorian and a Clinician Discuss Interpretation of Xpert MTB/RIF Results Mutation Detection with Molecular Beacons (Head containing wildtype SQ) Mutant Sequence Wildtype Sequence MB resting MB head does not bind to mutant SQ. Arms remain closed. No signals produced. MB in action! MB head binds to wildtype SQ. Arms open. Fluorophore away from quencher. Signals produced. Ct: Threshold Cycle at which signal crosses threshold Low DNA in the specimen High Ct 0 Sample (Wildtype) Ct=8 Threshold PCR Cycle September 6, 08 6
7 Fluorescence produced by probe binding Fluorescence produced by probe binding Experts on Xpert: A Laboratorian and a Clinician Discuss Interpretation of Xpert MTB/RIF Results 0 Ct: Threshold Cycle at which signal crosses threshold Low DNA in the specimen High Ct Sample (Wildtype) Ct=8 Ct= Sample (Wildtype) Threshold PCR Cycle 3 Ct: Threshold Cycle at which signal crosses threshold Low DNA in the specimen High Ct 0 Ct=8 Sample (Wildtype) Ct= Sample (Wildtype) 0 Threshold Sample PCR Cycle 4 September 6, 08 7
8 No signals: 3 possibilities Mutation(s) present MTBC DNA insufficient or not present Smear-negatives (if < ~0 colonies/ml) Unable to generate enough DNA copies Smear positive but not MTBC Inhibitory substance Inhibit amplification Xpert has internal control (SPC) to detect this Signals in SPC indicate no inhibitory substance in specimen Xpert interpretatiom-curry Center-9/6/8 Critical Rules for Interpretation (Set by the Xpert software) MTBC detected at least probes are positive RIF-R detected If highest and lowest Ct differs by more than 4 (Δ Ct max > 4) See more rules in package insert 6 September 6, 08 8
9 Typical Xpert results (Examples showing Xpert s rules work as intended -- No nuance!) 7 Ct End-pt MTBC: Not detected No probe has signal SPC has signal. If no signal, test is invalid. 8 September 6, 08 9
10 Ct Ct End-pt End-pt MTBC detected probes up RIF-S No mutation Δ Ct max < 4 ( =.) 9 Ct End-pt MTBC detected 4 probes up RIF-R detected Probe E no signals Δ Ct max > 4: 4.8-0=4.8 Most common MDR mutation: S3L, detected by probe E 0 September 6, 08 0
11 September 6, 08 Xpert Probes: Coverage of rpob Codon # Most common mutation confers resistance (3 TTG) Ask your lab which probe resulted in the RIF-R result Can Xpert differentiate M. tuberculosis (MTB) from M. tuberculosis complex (MTBC)? Xpert interpretatiom-curry Center-9/6/8
12 M. tuberculosis Complex M. tuberculosis M. bovis M. africanum M. caprae M. pinnipedii M. microti M. mungi, M. orygis, M. canettii, M. suricattae (proposed) All cause tuberculosis Xpert interpretatiom-curry Center-9/6/8 3 MTB / MTB Complex? Species in the MTB complex have same rpob core region sequence Xpert can only identify MTBC, not MTB species. MTBC is the correct term. Xpert results for M. tuberculosis and M. bovis indistinguishable 4 September 6, 08
13 Complications encountered in the real world TB clinic Apply your new knowledge of the hidden info on the Xpert computer Xpert interpretatiom-curry Center-9/6/8 The problems Silent mutations Xpert software does not know they are silent Interprets as RIF-R Smear-negatives (low MTBC DNA) May falsely detect RIF-R May falsely identify NTM as MTBC [rare] Dead bugs Xpert finds DNA; cannot distinguish between alive and dead organisms Xpert interpretatiom-curry Center-9/6/8 6 September 6, 08 3
14 Case 70 yo man born in Mexico Cough, wt loss, night sweats x months CXR shows left upper lobe infiltrate Sputum is smear positive Xpert is ordered Xpert interpretatiom-curry Center-9/6/8 7 Ct Ct End-pt MTBC detected 4 probes up RIF-R detected Probe B (no signals) Caution: Most common Silent mutation in probe B 8 September 6, 08 4
15 Xpert Probes: Coverage of rpob Codon # Most common silent mutation (4 TTT) Ask your lab which probe resulted in the RIF-R result 9 Big surprise! ~0% of all the mutations detected in the rpob core region are Silent! (In California and other low MDR areas) Most common is 4TTT Mutations detectable by probe B: 70% is this silent mutation Disputed mutation: 6TAC, 6TTC, RIF-R mutations: 6GTC, 3AAA, GAA, etc. Pennan, how to deal with probe B mutations? Xpert interpretatiom-curry Center-9/6/8 30 September 6, 08
16 Number and Proportion MDR-TB by Country/Region of Origin, CA 0 0 Country/Region No. % Former Soviet Republics. Laos 6. Burma 3.4 India 3. Guatemala 3.0 Korea (N&S) 7.9 Peru.6 Ethiopia.0 Philippines 7.7 Vietnam 3.4 China (incl Taiwan) 7. United States Cambodia 0.7 Mexico 0.6 Countries with >3 cases tested for MDR 3 Number and Proportion MDR-TB by Country/Region of Origin, CA 0 0 Country/Region No. % PPV (99% spec) PPV (98% spec) Former Soviet Republics. 93% 87% Laos 6. 84% 7% Burma % 63% India 3. 7% 60% Guatemala 3.0 7% 60% Korea (N&S) % 9% Peru.6 7% 6% Ethiopia.0 66% 0% Philippines 7.7 6% 4% Vietnam 3.4 7% 40% China (incl Taiwan) 7. 4% 37% United States % 8% Cambodia % % Mexico % % Countries with >3 cases tested for MDR 3 September 6, 08 6
17 MDR-TB Cases by Country/Region of Origin and Years in the US, CA 0 0 Country/Region Total MDR TB cases years in US No. (%) > years in US No. (%) All Countries* (excl U.S.) (3.7) 7 (.) Vietnam* 3 9 (7.9) 3 (0.4) China* (incl Taiwan) 7 (8.8) (0.4) Philippines* 7 8 (4.0) 9 (.4) * Difference is statistically significant 33 Order Xpert or PSQ for Patients with MDR Risk! MDR risks: Prior TB treatment Contact to patient with drug resistant TB Non-U.S.-born from country with increased MDR risk ( % MDR among TB cases in California) Arriver to U.S. within years HIV positive Among 4 smear positive MDR cases with MDR risk, 0 did not get Xpert or PSQ on sputum (California, 0-06) Lowenthal, NTCA/CTCA poster September 6, 08 7
18 Probe B Interpretation Interpret in clinical context Are there risks for DR TB? Is there a pressing need to start treatment immediately? In this case: born in Mexico, no prior treatment, not a contact probably silent Pyrosequencing: 4TTT (Silent mutation) 3 Testing smear-negative samples 36 September 6, 08 8
19 Case 30s yo F cough x 4 weeks No prior TB treatment Born in country with low MDR prevalence; no travel Household contact to pan-s case year prior Xpert interpretatiom-curry Center-9/6/8 37 MTBC Detected RIF-R detected High Cts ΔCt = = September 6, 08 9
20 MTBC Detected RIF-R not detected High Cts ΔCt = =.9 39 Case Treated with RIPE Clinically improved after week Pyrosequencing: no amplification DSTs: PanS Xpert interpretatiom-curry Center-9/6/8 40 September 6, 08 0
21 Xpert MTB/RIF Performance on Smear Negative Sputum Compared with Culture, U.S. patients Sensitivity Specificity Xpert Xperts 9.3% (6/7) 7.4% (0/8) 99.% Should we always test two samples? Luetkemeyer Clin Infect Dis 06 4 Case 3 0 yo man born in Mexico, in U.S. for 0 yrs 6 weeks of cough, night sweats CXR RUL nodular infiltrate No MDR contact, no prior treatment All smears are negative Xpert pending Order testing samples to increase sensitivity!? 4 September 6, 08
22 Sample # Sample # MTBC not detected MTBC detected Rif Resistance not detected Conflicting results! Shall I worry false positivity? Ask lab to test another specimen!? Xpert interpretatiom-curry Center-9/6/8 43 Sample 3 Sample 4 MTBC detected Rif resistance indeterminate MTBC detected Rif resistance detected Sample #3 results were indeterminate. Order another test!! Sample #4 results were RIF-R. Hit the jackpot! 4 tests 4 different results! 44 September 6, 08
23 Problems with testing smear-negatives MTBC DNA Low, very low or not present Xpert s detection limit is about 0 CFU/mL Xpert results less reproducible, because: Reduced amplification: generate fewer amplicons PCR efficacy varies between runs Reduced probe binding: generate less signals Probe s binding efficacy varies more among probes Increased Δ Ct max: Increased false RIF-R detection Xpert interpretatiom-curry Center-9/6/8 4 Follow-up actions MTBC not detected Does not rule out MTBC. Consider second Xpert Wait for culture results. MTBC detected Rifampin resistance not detected Most reliable MTBC detected Rifampin resistance detected Need to be confirmed by sequencing. MTBC detected Rifampin resistance indeterminate [not discussed today] Likely happens when testing smear-negatives. If this is a first test, test nd specimen. If this is a nd test. Wait for culture results. Xpert interpretatiom-curry Center-9/6/8 46 September 6, 08 3
24 Two probes positive = MTBC? This is a dangerous rule! Especially when the sample is smear-negative Two probes pos = 3 or more mutations Very RARE to have 3 mutations within 8 bp Out of 374 tested, samples had 3 mutations (MDL data) None detected by 3 probes! One detected by probes (A & B) One detected by probe (D) Xpert interpretatiom-curry Center-9/6/8 47 When should NTM be suspected? Smear-negative Only two probes are positive. Xpert reports MTBC and RIF-R detected. Smear-positive Multiple Xperts: MTBC not detected Xpert interpretatiom-curry Center-9/6/8 48 September 6, 08 4
25 Can we use Xpert for detection of relapses? Xpert interpretatiom-curry Center-9/6/8 49 Case 4 70 yo man from China years ago treated for cavitary TB with RIPE cured Presents to ED with days of SOB, no fever, night sweats or weight loss (weight gain) CXR with bilateral pleural effusions Smear neg, Xpert positive, RIF-R (Probe A) No sequence detected by PSQ Culture grew a rapid grower DNA of the isolate from years ago, showed rpob CCG (detectable by probe A) Kelly et al Am J Resp Crit Care Med 04 0 September 6, 08
26 Case 4 History concerning for MDR Clinical presentation atypical for TB, more compatible with CHF Treated for weeks then stopped All cultures negative, including mos later Negative cultures and same rpob mutation as prior --> dead bugs? Kelly et al Am J Resp Crit Care Med 04 Xpert positivity on treatment Insert figure from publication 7% Weeks after treatment initiation Friedrich, Lancet Respir Med 03; : September 6, 08 6
27 Don t get Xpert after treatment start or in previously treated patients Xpert cannot determine alive vs dead Xpert can remain positive for years after curative treatment Package insert recommends against Xpert in anyone treated for >3 days If you order it, only helpful if different RIF result from prior (e.g., a previously pan-s case has a probe E RIF-R result) 3 Summary Points Order Xpert! If results surprise you, talk to your lab! Ask for probe and Ct info Interpret in clinical context How likely is it that this patient has TB and DR-TB? MDR risk factors? Prior treatment, contact to MDR case, born in country with high MDR prevalence? Can you wait for culture results? Get rpob sequencing for all RIF-R specimens If smear negative (Ct > 8), wait for culture Xpert interpretatiom-curry Center-9/6/8 4 September 6, 08 7
28 Ed Desmond Phil Lowenthal Neha Shah MDR Service Microbial Disease Lab Acknowledgments Leslie Phil Pennan Henry Lowenthal Barry Jenny Flood Neha Shah Gayle Schack (Ret) Lisa True Kristen Christy Pak Wendorf (Ret) Not pictured: Shereen Katrak Wendy Cheung Stephen Yu Grace Lin Terry Weber Lucy Pham Zachraias Zachraias Kitty Reiher Amelia Alonis Thank You! Xpert interpretatiom-curry Center-9/6/8 6 September 6, 08 8
29 Resources California Microbial Diseases Lab PSQ: Screening.pdf Curry/CDPH MDR TB Survival Guide Lab Chapter: laboratory CDC TB Lab: NTCA/APHL Consensus Statement on Xpert for release from isolation: Khan academy PCR unit: Xpert MTB/RIF Package Insert: files/f6a0c86cd73ce46ba39c4a3eabc4-3a9ca7ef6b9b88dc736ea437f4eb3a-xpert-mtbrif-english-packageinsert Rev-C.pdf 7 rpob Facts Most common mutation conferring RIF-R rpob 3TTG detectable by Probe E nd most common mutation conferring RIF-R rpob 6TAC & 6GAC detectable by probe D Most common silent mutation rpob 4TTT detectable by probe B (>0% of all mutations) Disputed mutations are not common, but are detectable But you would not know unless sequenced. Not common to have mutations, very rare to have 3 mutations. Even more rare to have 3 mutations detected by 3 probes. 8 September 6, 08 9
30 rpob codon numbering change Historically rpob codons numbered with E. coli All other loci numbered according to M. tuberculosis Change to M. tuberculosis numbering to align with whole genome sequencing data Good news: just subtract MDL has started using MTBC numbering (As of 8//8) Codon conversion info provided in comment Xpert interpretatiom-curry Center-9/6/8 9 Xpert Ultra WHO recommends the use of Ultra. specific targets for detection of MTBC IS60 & IS08 Increased sensitivity for MTBC detection 66% (G4) vs 79% (Ultra) Added a step to analyze melting temperature for identification of specific mutations. 4 sloppy MB probes for detecting rpob mutations. F4F Silent mutation is not detected. Great news! 60 September 6, 08 30
Laboratory Diagnosis for MDR TB
Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe
More informationCalifornia TB program updates
California TB program updates CAPHLD Conference Nov 6, 2017 Pennan Barry, M.D., M.P.H. Chief, Surveillance and Epidemiology Section Lead MD, California MDR TB Service pennan.barry@cdph.ca.gov Outline California
More informationShah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED
/7/6 Discordant Growth- Molecular Diagnos7c Challenges and Treatment Outcomes Neha Shah, MD MPH Centers for Disease Control and Preven7on California Department of Health Tuberculosis Control NAR February
More informationKen Jost, BA, has the following disclosures to make:
Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict
More informationHarmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis
Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13 Harmonizing? There
More informationUse of the Cepheid GeneXpert to Release Patients from Airborne Isolation
Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation Dave Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene WISCONSIN STATE LABORATORY
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationDiagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014
TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationEssential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective
Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective James Watt, MD, MPH Acting Chief, Tuberculosis Control Branch California Department of Public
More informationTB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012
TB Nurse Case Management San Antonio, Texas March 7-9, 2012 Diagnosis of TB: Laboratory Ken Jost Wednesday March 7, 2012 Ken Jost has the following disclosures to make: No conflict of interests No relevant
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Diagnosis of TB: Laboratory Ken Jost, BA November 12, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationXpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it
Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it Angela Starks, PhD Chief, Laboratory Branch Division of TB Elimination Matt Bankowski, PhD, MS, D(ABMM), HCLD/CC(ABB)
More informationTB in California: Costs, Transmission, and Selecting from the Latent Pool
TB in California: Costs, Transmission, and Selecting from the Latent Pool Pennan Barry, MD, MPH Tuberculosis Control Branch California Department of Public Health California Tuberculosis Controller s Association
More informationNAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL
NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL Susan Novak-Weekley, S(M), ASCP, Ph.D., D(ABMM) Director of Microbiology,
More informationA Rapid and Sensitive Chip-based Assay for Detection of rpob Gene Mutations Conferring Rifampicin Resistance in Mycobacterium tuberculosis (TB).
A Rapid and Sensitive Chip-based Assay for Detection of rpob Gene Mutations Conferring Rifampicin Resistance in Mycobacterium tuberculosis (TB). Wanyuan Ao, Steve Aldous, Evelyn Woodruff, Brian Hicke,
More informationDST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?
DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps? Mark Nicol Division of Medical Microbiology and Institute for Infectious Diseases and
More informationClinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis
Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers
More informationEpidemiology and diagnosis of MDR-TB in children H Simon Schaaf
Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions
More informationTB NAAT testing at the Los Angeles County Public Health Laboratory
TB NAAT testing at the Los Angeles County Public Health Laboratory Hector Rivas Public Health Microbiology Supervisor II Los Angeles County Public Health Laboratory hrivas@ph.lacounty.gov April 2012 1
More informationUsing Xpert to discontinue airborne isolation The Consensus Statement
Using Xpert to discontinue airborne isolation The Consensus Statement Neha Shah, MD MPH Tuberculosis Control California Department of Public Health Centers for Disease Control and Prevention NAR February
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationWELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears
Lab Talk: What a Lab Talk: What a Max Salfinger, MD, FIDSA, FAAM Executive Director, Advanced Diagnostic Laboratories Laboratory Director, Mycobacteriology & Pharmacokinetics National Jewish Health Lisa
More informationTB 101 Disease, Clinical Assessment and Lab Testing
TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain
More informationStacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona
Role of the Laboratory in TB Diagnosis Stacy White, PhD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Stacy White, PhD has the following disclosures
More informationANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
More informationCDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California
CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California These guidelines are intended to be used as an educational aid to help clinicians make informed decisions about patient
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationDr Francis Ogaro MTRH ELDORET
Dr Francis Ogaro MTRH ELDORET TB in children often severe, disseminated and can progress rapidly and with poor outcome TB diagnosis in children has relied on clinical, imaging, microscopy and TST findings.
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More information2018 Tuberculosis Clinical Intensive: Infection Prevention & Control. > No disclosures
2018 Tuberculosis Clinical Intensive: Infection Prevention & Control > No disclosures 1 Objectives By the end of today s session, hopefully you will be able to: > Recognize potential TB exposures in healthcare
More informationXpert MTB/RIF Training. Indira Soundiram 2012
Xpert MTB/RIF Training Indira Soundiram 2012 A Better Way to Platform Design GeneXpert Infinity-48 GeneXpert Module GX-I GX-II GX-IV GX-XVI 2 Defining Molecular Diagnostics Any Test Any Time Any Sample
More informationA retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece
Örebro University School of Health and Medical Science Biomedical Laboratory Science Programme 180 credits Degree project in biomedical laboratory science, advanced course, 15 credits May 21, 2015 A retrospective
More informationNucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services
Nucleic Acid Amplification Test for Tuberculosis Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services What is this test? Nucleic Acid Amplification Test (NAAT)
More informationMIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex
MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex Marie Claire Rowlinson, PhD D(ABMM) Florida Bureau of Public Health Laboratories
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More informationResearch Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012
Research Methods for TB Diagnostics Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012 Overview Why do we need good TB diagnostics? What works? What doesn t work? How
More informationWhen good genes go bad
When good genes go bad Dr Kessendri Reddy NHLS Tygerberg Hospital Division of Clinical Microbiology Fakulteit Geneeskunde en Gesondheidswetenskappe Faculty of Medicine and Health Sciences Overview Cases
More informationTB Classification (ATS/CDC)
bits and pieces Lisa Chen, MD UCSF Pulmonary/Critical Care Curry International Tuberculosis Center 10/2017 TB Classification (ATS/CDC) TB0 No tuberculosis exposure, not infected TB1 Tuberculosis exposure,
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationThe Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis
The Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis DR. PHYLLIS DELLA-LATTA, D(ABMM), FAAM DIRECTOR, CLINICAL MICROBIOLOGY SERVICE PROFESSOR, CLINICAL PATHOLOGY
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationWSLH Testing and Surveillance Updates
WSLH Testing and Surveillance Updates Wisconsin Mycobacteriology Laboratory Network annual conference November 4, 2015, Madison, WI Updates Outline Collection and Transport Smear and Culture Nucleic Acid
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationCDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service
CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service Beverly Metchock, DrPH, D(ABMM) Team Lead, Reference Laboratory
More informationMolecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.
Title Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium. Author(s) Ho, PL; Yam, WC; Leung, CC; Yew, WW; Mok, TYW; Chan, KS; Tam, CM Citation Hong Kong Medical
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationKritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen
Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen Hans L Rieder Union Internationale Contre la Tuberculose et
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationAppendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)
Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes
More informationThe diagnosis of active TB
The diagnosis of active TB Faculty/Presenter Disclosure Faculty: Martha Ainslie Relationships with commercial interests: Speakers Bureau/Honoraria: Boehringer Ingelheim Mitigating Potential Bias I have
More informationDisclosure. Objectives
Breaking the Chain of TB Airborne Isolation Regina McDade EdD, MPH, BSN, RN TB Clinical Care Coordinator Jackson Health System Department of Infection Prevention and Control David Ashkin, M.D. FCCP Medical
More informationAppendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)
Appendix B Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997) Since publication of the Recommendations for Counting Reported Tuberculosis Cases 1 in January 1977, numerous changes
More informationNucleic Acid Amplification Testing for the Diagnosis of TB
Roche Nucleic Acid Amplification Testing for the Diagnosis of TB David Warshauer, PhD Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene 19 th /20 th Century Traditional Algorithm
More informationDiagnosis of tuberculosis in children
Diagnosis of tuberculosis in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Estimated TB incidence
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationPediatric TB Intensive Houston, Texas October 14, 2013
Pediatric TB Intensive Houston, Texas October 14, 2013 Diagnosis and Management of Tuberculosis in Adolescents Andrea T. Cruz, MD, MPH Sections of Infectious Diseases & Emergency Medicine October 14, 2013
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationResearch in Tuberculosis: Translation into Practice
Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Case Presentations Doug Hornick, MD; Iowa U Medical School December 1, 2010 Pulmonary Fascinomas with a Tuberculous Attitude Douglas B. Hornick, MD
More informationSupplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining
Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining of PBMCs. Forward scatter area (FSC-A) versus side scatter area (SSC-A) was used to select lymphocytes followed
More informationRevised Technical Instructions for Civil Surgeons. October 9, 2018
Revised Technical Instructions for Civil Surgeons October 9, 2018 Speakers Joanna Regan Centers for Disease Control and Prevention Shereen Katrak California Department of Public Health Pennan Barry California
More information2008 Tuberculosis Report
2008 Tuberculosis Report County of Sacramento Department of Health and Human Services Division of Public Health Page 1 Table of Contents Figure 1. Tuberculosis Incidence Rates, County of Sacramento Vs
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationTB Contact Investigation
Ann Raftery, RN, PHN, MS Curry International TB Center Overview Contact investigation as a core TB control and elimination activity Components of TB Contact Investigation TB Control Priority Strategies.
More informationHow Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008
How Is TB Transmitted? Sébastien Gagneux, PhD 20 th March, 2008 Today s Outline 1) Global spread of Mtb Comparative genomics Phylogeny 2) Transmission of drug-resistant Mtb Fitness assays Molecular epidemiology
More informationSelected highlights: Treating Drug resistant TB: High resource, low incidence settings
Selected highlights: Treating Drug resistant TB: High resource, low incidence settings Regional Training and Medical Consultation Centers (RTMCCs) Pennan Barry, Lisa Chen, Connie Haley, Alfred Lardizabal,
More informationIssues in TB Infection Control. Stopping transmission of TB. The Issue: Transmission of TB. TB Infection Control
Curry International TB Center Issues in TB Infection Control Lisa Chen, MD CITC TB Intensive, Oct. 2017 Stopping transmission of TB TB Infection Control A combination of measures aimed at minimizing the
More informationChanging TB Isolation Practices: Consensus Statement Concerning the Incorporation of Molecular Testing
Dave Ashkin, MD, FCCP Changing TB Isolation Practices: Consensus Statement Concerning the Incorporation of Molecular Testing 07/20/2016 1 Dave Ashkin, MD, FCCP Staff TST in Four Hospitals with MDR-TB Outbreak
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationTB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai
TB/HIV 2 sides of the same coin Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai Global- Tb new cases Diagnosis-Microscopy ZN,Flourescent microscopy(fm) Rapid, inexpensive test Specificity>95%
More informationTB Laboratory for Nurses
TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationThe need for new TB diagnostics in children and the way forward
The need for new TB diagnostics in children and the way forward Steve Graham Centre for International Child Health University of Melbourne Department of Paediatrics Royal Children s Hospital Melbourne
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationThe Lancet Infectious Diseases
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study Susan E Dorman, Samuel G Schumacher, David Alland et al. 2017
More informationHow best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
More informationLaboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients
Laboratory services for the diagnosis and management of TB, MDR-TB, XDR-TB in HIV co-infected patients Max Salfinger Fogarty Workshop on TB/HIV Cali, Colombia - March 28, 2007 John E. Fogarty Bricklayer;
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationCase Study: TB-HIV co-infection
Case Study: TB-HIV co-infection Julia Greenleaf, RN, MPH Public Health Nurse Public Health Madison & Dane County With guest appearance by Julie Tans-Kersten, MS, BSMT (ASCP) Director, WI TB Program 33
More informationI. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %
San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7
More informationTB-Free California: How close are we? How can we get closer?
TB-Free California: How close are we? How can we get closer? California TB Controllers Association April 21, 2015 Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology Section Acknowledgments Local
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationTreatment of TB. David Griffith, MD May 12, TB for Community Providers. Phoenix, Arizona
Treatment of TB David Griffith, MD May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION David Griffith, MD has the following disclosures to make: No conflict
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationUtilizing All the Tools in the TB Toolbox
Utilizing All the Tools in the TB Toolbox Sandra Morano, B.A., R.N. Public Health Nurse, City of Stamford, CT TB Talk The New England TB Consortium March 18, 2010 Background TB Program, City of Stamford,
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationXpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10
Xpert MTB/Rif What place for TB diagnosis in MSF projects? Francis Varaine, MSF Geneva, 29/11/10 Introduction Excellent performances, rapid results, and easy to use Questions Where and how are we going
More information